New Seed Train Platform Intensifies Upstream Processing

Merck have announced the launch of the BioContinuum™ Seed Train Platform, the industry’s only integrated and versatile solution enabling biomanufacturers to confidently move toward next generation bioprocessing using seed train intensification.

The platform consists of proprietary products for N-1 perfusion and high cell density cryopreservation (HCDC) including: the off-the-shelf Cellvento® 4CHO-X Expansion Medium specifically designed for seed train expansion and N-1 perfusion, the Cellicon™ Perfusion Solution for superior cell retention, and closed processing-ready Mobius® HCDC R&D single-use assemblies for high cell density cryopreservation.

集成的BioContinuum™种子序列平台解决了对高效、一致的种子序列的需求，支持增加细胞密度，以强化氮生产过程。具体来说，它能够提高生产阶段的单克隆抗体生产率，减少工厂占地面积和利用率，并加快生产时间。该平台支持的强化工艺是完全封闭的，与补料批次和灌注氮生产阶段兼容，提供了最大的灵活性。种子列车集约化提高了效率，减少了劳动力需求和操作复杂性，而且由于过程是封闭的，污染的风险大大降低。

Seed train intensification is the first step toward optimisation of the entire upstream workflow, enabling biomanufacturers to realise the time and cost savings for fed-batch and perfusion processes. At a time when many manufacturers of monoclonal antibodies are seeking to add capacity to support growing demand, process intensification increases flexibility and reduces manufacturing footprint to realise their facilities' full potential.

More informationonline